Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple sclerosis (MS) failed to meet its primary endpoint. The study aimed to determine whether treatment with ...

For further information on how we select topics for development, please see our page about topic selection ...

WEST PALM BEACH, Fla. — Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, findings confirmed by data from a series of ...

That program allows patients who do not qualify for an ongoing Phase 2a clinical… Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS ...

The MUSETTE trial found no additional benefit in higher doses of ocrelizumab for RMS compared to the standard 600 mg dose. The 600 mg dose of ocrelizumab remains optimal for slowing disability ...

Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) is a prescription drug that’s used to treat certain forms of multiple sclerosis (MS). Ocrevus Zunovo comes as a ...